SCHEMBL3604333

SCHEMBL3604333

NCc1c(-c2ccc(F)cc2Cl)ncn1Cc1ccccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 4/20 0.44
PHF8 Q9UPP1 1/20 0.39
HSD11B1 P28845 1/20 0.39
DPP4 P27487 4/20 0.39
ACP1 P24666 1/20 0.37
POLB P06746 1/20 0.37
ALDH1A1 P00352 3/20 0.36
P2RX7 Q99572 2/20 0.36
KDM2B Q8NHM5 1/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PNMT P11086 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3092256 0.92 CNR1 (0.39) KDM4CHSD11B1DPP4ALDH1A1
SCHEMBL3091396 0.92 KDM4C (0.43) KDM4CPHF8DPP4ACP1POLB
SCHEMBL3078422 0.92 ALDH1A1 (0.38) KDM4CDPP4ALDH1A1P2RX7LMNA
SCHEMBL3089615 0.91 P2RX7 (0.42) KDM4CPHF8HSD11B1DPP4P2RX7
SCHEMBL3092637 0.90 P2RX7 (0.41) KDM4CHSD11B1DPP4ALDH1A1P2RX7
SCHEMBL3096019 0.88 DPP4 (0.45) HSD11B1DPP4MEN1KMT2A
SCHEMBL3084580 0.88 DPP4 (0.49) PHF8DPP4ACP1P2RX7
SCHEMBL3598866 0.88 HSD11B1 (0.43) KDM4CHSD11B1ALDH1A1P2RX7
SCHEMBL3092355 0.87 DPP4 (0.42) DPP4ACP1ALDH1A1P2RX7LMNA
SCHEMBL3102196 0.87 BCL2L2 (0.42) KDM4CHSD11B1DPP4P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7728146-B2 Enzyme inhibitors PROBIODRUG AG (DE) 2010-06-01 US claimed
US-20100234397-A1 ENZYME INHIBITORS PROBIODRUG AG (DE) 2010-09-16 US disclosed
US-20100234397-A1 ENZYME INHIBITORS PROBIODRUG AG (DE) 2010-09-16 US disclosed
US-7728146-B2 Enzyme inhibitors PROBIODRUG AG (DE) 2010-06-01 US disclosed
US-7728146-B2 Enzyme inhibitors PROBIODRUG AG (DE) 2010-06-01 US disclosed
US-20070244177-A1 ENZYME INHIBITORS PROBIODRUG AG (DE) 2007-10-18 US disclosed
US-20070244177-A1 ENZYME INHIBITORS PROBIODRUG AG (DE) 2007-10-18 US disclosed
WO-2007116092-A1 ENZYME INHIBITORS PROBIODRUG AG (DE) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244177-A1 ENZYME INHIBITORS ACHE, BACE1, MAOA KDM4C 1750/4885PHF8 2383/4885HSD11B1 218/4885
US-20100234397-A1 ENZYME INHIBITORS ACHE, MAOA, BACE1 KDM4C 2011/4885PHF8 2405/4885HSD11B1 258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.